Short-course aminoglycoside therapy in patients with spinal cord injury. Standard dose versus low dose.
Twenty-nine patients with spinal cord injury and asymptomatic urinary tract infection were treated with standard or reduced doses of tobramycin and amikacin. The patients received five days of intramuscular antibiotics. Most of the patients in the tobramycin groups had Pseudomonas aeruginosa infection and most of those in the amikacin group had either Proteus rettgeri or Providencia stuartii infections. Only 1 patient had a positive urine antibody coating test. High antibiotic concentrations were demonstrated in the urine of all patients during therapy. Urine cultures were obtained two and seven days after completion of therapy. Forty-eight per cent of the patients were cured, while 31 per cent showed persistence or relapse, and 21 per cent had reinfection with other bacteria. No significant differences in results were observed between the standard-dose and low-dose regimens and between the amikacin and tobramycin groups. The low success rate of the regimens used may indicate the need to evaluate alternative therapeutic regimens to treat urinary tract infections in this special group of patients.
D000328:Adult; D000583:Amikacin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000031:analogs & derivatives*; D011512:Proteus Infections / Q000188:drug therapy; D011532:Providencia; D011552:Pseudomonas Infections / Q000188:drug therapy; D011897:Random Allocation; D012008:Recurrence; D013119:Spinal Cord Injuries / Q000150:complications*; D014031:Tobramycin / Q000008:administration & dosage*; D001750:Urinary Bladder, Neurogenic / Q000209:etiology; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D007612:Kanamycin; D000583:Amikacin; D014031:Tobramycin